LES 2008 Annual Meeting
Oct. 19, 2008-Oct. 23, 2008Gaylord Palms Resort and Convention Center
Orlando, FL
www.usa-canada.les.org/meetings/2008annual/index.asp
Description:
What Buyers Want: Understanding What Big Pharma In-Licensors Expect to See in Out-Licensing Documents
Ben Bonifant, Vice President and head of our Business Development Practice will participate in two panel discussions at this year's event. In the first session, Mr. Bonifant and panelists from Arena Pharma, Pfizer and Sanofi Aventis will discuss the importance of understanding what in-licensors expect to see in out-licensing materials. In the second panel, Mr. Bonifant and panelists from Bristol-Myers Squibb and Solvay will discuss how to identify and prioritize the right therapeutic areas of opportunity.
Abstract:
What Buyers Want: Understanding What Big Pharma In-Licensors Expect to See in Out-Licensing Documents
While the number varies depending on the size of a given therapeutic area, business development professionals at most of the top 10 pharmaceutical and biotech companies review hundreds of non-confidential documents each year to evaluate compounds' in-licensing potential. Out-licensors invest a significant amount of time and resources developing non-confidential documents to help elucidate their products' attributes in the hope of landing that much-needed deal, but what are the key characteristics of a product or company that lead licensing reviewers to move to confidential discussions?
Panelists:
Ben Bonifant, Vice President, Business Development Practice, Campbell Alliance
Joanne Smith-Farrell, Senior Director, Worldwide Business Development & Licensing, Pfizer
Carole Wilmot, Senior Director, U.S. Licensing, Sanofi Aventis
Choosing Where to Focus: How to Identify and Prioritize the Right Therapeutic Areas of Opportunity
Until recently, large pharmaceutical companies focused on developing primary care products with blockbuster potential. But leading companies are now moving in a new direction, placing their bets on specialty therapeutic areas that were once more commonly pursued by growth-oriented biotech or specialty pharmaceutical companies. This shift in strategy was driven by several factors, including the realization that primary care blockbusters are less common than in previous years, the proportionally greater number of specialty compounds (out of the overall number of compounds) available for licensing from smaller companies, and the need to fill pipeline gaps. Regardless of their rationale, the initial step in—and a significant hurdle to— pursuing this specialty model is selecting therapeutic areas or disease states on which to focus.
Ben Bonifant, Vice President, Business Development Practice, Campbell Alliance
Paul Biondi, Vice President, R&D Operations, Bristol-Myers Squibb
Frank Jaeger, Associate Director, New Business Development, Solvay Pharmaceuticals
Feature Articles
George Schmidt, Senior Vice President of the Sales Practice, discusses the impact of the current pharma and biotech landscape on sales forces and Training & Development departments....
Don't Miss
Campbell Alliance will exhibit at this event. Please visit us at booth # 5240. Also at the event, the Business Development Practice will be participating in partnering meetings in the Business Forum.
Webster Sun, Senior Practice Executive, Brand Management Practice, will moderate a panel discussion on the opportunities and challenges surrounding generic versions of many blockbuster biopharmaceutical products following their patent expiration.
Emily Hua, Vice President, Brand Management Practice, will moderate a panel discussion on first-to-market strategies and key lessons learned.
Kevin Barnett, Senior Vice President and Head of the Managed Markets Practice, Campbell Alliance and the Pharmaceutical Institute will participate in a panel discussion on health care reform and the potential implications for the life science industry.
George Schmidt, Senior Vice President, and John Bye, Vice President ,Sales Practice, will lead workshops on staying strategic in today's environment, driving sales force effectiveness and building sustainable training programs.
Campbell Alliance's Trade and Distribution Practice will exhibit at this event. Please visit us at booth #420.
Darius Naigamwalla, Senior Vice President and Global Practice Area Lead, and Tom Luginbill, Vice President, Brand Management Practice, lead a workshop on best practices for commercial planning and the requirements at each stage of the development process.
Keith Morris, Practice Executive, will present a session on successful communication strategies for effective execution of post-approval studies.
Joe Dillon, Senior Practice Executive, Campbell Alliance, will lead a discussion on maximizing the value of product candidates and technologies through a structured deal approach.
Kevin Barnett, Senior Vice President and Practice Area Lead, Managed Markets Practice will serve as chairman for the conference, as well as present a session on how to avoid common mistakes when contracting with payers.
Barrett Rankin, Practice Executive, Business Development Practice, will present a session on linking portfolio management with business development.
Executives from our Brand Management and Managed Markets Practice will have leadership roles at this event.
Kevin Barnett, Senior Vice President and Practice Area Lead, Managed Markets Practice, will present a session on developing and communicating a payer value proposition.
Campbell Alliance's Managed Markets Practice will exhibit at this event.
Campbell Alliance's Trade and Distribution Practice will exhibit at this event.
Executives from our Business Development Practice will moderate two panel discussions at this event.
Leaders from the Brand Management Practice will present a pre-conference workshop on strategies and best practices for managing the logistics of launch, while leaders from the Managed Markets Practice will present a health policy outlook for 2010.
Tony Lanzone, Vice President and head of the Trade and Distribution Practice at Campbell Alliance, will serve as conference chairman, while Jay Jauregui, also of the Trade and Distribution Practice, will present on developing a specialty distribution strategy.
Keith Kelly, Senior Practice Executive, Managed Markets Practice, will present a session on developing a managed care marketing strategy
Campbell Alliance is a sponsor of this event and executives within the Brand Management and Clinical Development Practices will attend.
Darius Naigamwalla, Senior Vice President and Global Practice Area Leader, Brand Management Practice, will present a session on systematically building commercial innovation into oncology launch plans. Also, Tony Lanzone, Vice President, Managed Markets Practice, will present a session on the evolving pricing, reimbursement, and access environment for oncology products.
Gary Tyson, Senior Vice President, Clinical Development Practice, will present a session on leveraging effective SOPs to create a community of compliance and adherence.
Gary Tyson, Senior Vice President, Clinical Development Practice, will present a session on the key learnings of CTMS implementation derived from the experiences of several organizations that have undergone implementation.
Three executives from our Business Development and Managed Markets Practices will present "Reimbursement: The New Investment Hurdle"
Darius Naigamwalla, Global Practice Area Leader, and Tom Luginbill, Vice President, both of the Brand Management Practice, will present a pre-conference workshop on strategies and best practices for strategically managing an oncology product launch. Also Tony Lanzone, Vice President in the Managed Markets Practice will moderate a payer panel discussion on the evolving pricing, reimbursement, and access environment for oncology products.
Mike Menta, Senior Practice Executive, Clinical Development Practice, will moderate a session on both opportunities and challenges of conducting clinical trials abroad.
Lujing Wang, Vice President, Managed Markets Practice, will present a session on evidence-based medicine in an evolving landscape for global market access.
Gautam Aggarwal, Senior Practice Executive in our Business Development Practice, will present the results and observations from Campbell Alliance's 2010 Dealmakers' Intentions Survey and moderate a panel discussion with leading business development decision makers.
Gautam Aggarwal, Senior Practice Executive, Business Development Practice, will present the results and observations from Campbell Alliance's Dealmaker's Intentions Survey.